Journal of Psychopharmacology
September 12, 2025
Stephan Tap, Kelan Thomas, Tomáš Páleníček et al.
5 citations
Classic psychedelics are increasingly studied as potential treatments for different psychiatric disorders. Current research protocols often require patients to discontinue antidepressants (ADs) for at least 2 weeks before psychedelic administration to decrease the risk of serotonin syndrome and limit their effect on efficacy and the acute subjective effects of psychedelics. Moreover, the...
Current Topics in Behavioral Neurosciences
July 24, 2024
Kelan Thomas
3 citations
As psychedelics are being investigated for more medical indications, it has become important to characterize the adverse effects and pharmacological interactions with these medications. This chapter will summarize what is known about the toxicology and drug-drug interactions for classic psychedelics, such as LSD, psilocybin, DMT, 5-MeO-DMT, mescaline, 2C-B, Bromo-DragonFLY, and 25X-NBOMe.
Journal of Psychoactive Drugs
2024
Kelan Thomas, Robert L. Jesse, Nicky J. Mehtani et al.
4 citations
In recent years, policymakers have proposed and implemented regulatory changes promoting the deprioritization, decriminalization, or state-level legalization of one or more psychedelic substances, usually referencing data from clinical trials as reasons to support liberalizing drug control policies. As psychedelic policies continue to be drafted, personal possession limits may be considered for...
Journal of the American College of Clinical Pharmacy
October 1, 2023
Kelan Thomas
In coming years, pharmacists will begin fielding more questions regarding psychedelic medicine, most notably with the imminent FDA approval of 3,4-methylenedioxymethamphetamine (MDMA) for posttraumatic stress disorder (PTSD) expected in 2024 and psilocybin for major depressive disorder (MDD) likely in 2025. Psychedelics are unique medications in many ways, but especially due to the mental...
Psychopharmacology
March 7, 2022
Aryan Sarparast, Kelan Thomas, Benjamin Malcolm et al.
85 citations
As MDMA and psilocybin continue to move through the FDA drug development process, this systematic review offers a compilation of existing research on psychiatric drug-drug interactions with MDMA or psilocybin.
Psychopharmacology
July 12, 2021
Benjamin Malcolm, Kelan Thomas
131 citations
RationaleIn recent years, psychedelic substances with serotonergic mechanisms have accumulated substantial evidence that they may provide therapeutic benefits for people suffering with psychiatric symptoms. Psychiatric disorders targeted by these psychedelic-assisted therapies are managed with serotonergic drugs like selective serotonin reuptake inhibitors (SSRIs) as the current standard of...
Scientific Reports
March 16, 2021
Isaac Cohen, Tigran Makunts, Ruben Abagyan et al.
30 citations
Abstract 3,4-Methylenedioxymethamphetamine (MDMA) is currently being evaluated by the Food and Drug Administration (FDA) for the treatment of post-traumatic stress disorder (PTSD). If MDMA is FDA-approved it will be important to understand what medications may pose a risk of drug–drug interactions. The goal of this study was to evaluate the risks due to MDMA ingestion alone or in combination...
Journal of Psychoactive Drugs
May 8, 2017
Kelan Thomas, Benjamin Malcolm, Dan Lastra
77 citations
Recent research suggests that functional connectivity changes may be involved in the pathophysiology of psychiatric disorders. Hyperconnectivity in the default mode network has been associated with psychopathology, but psychedelic serotonin agonists like psilocybin may profoundly disrupt these dysfunctional neural network circuits and provide a novel treatment for psychiatric disorders. We have...
Journal of Forensic Sciences
September 1, 2015
Paul J. Perry, Kristian Fredriksen, Stephanie Chew et al.
Dextromethorphan (DXM) is abused most commonly among adolescents as a recreational drug to generate a dissociative experience. The objective of the study was to assess driving with and without DXM ingestion. The effects of one-time maximum daily doses of DXM 120 mg versus a guaifenesin 400 mg dose were compared among 40 healthy subjects using a crossover design. Subjects' ability to drive was...